Apollo Diagnostics
Non-invasive multivariate cancer biomarkers and signatures for early disease detection
About
For cancer patients and pharmaceutical companies worldwide who annually spend over 10 billion dollars on biomarker discovery and diagnostics, Apollo’s multivariate highly sensitive and specific non-invasive cancer signatures would predict clinical performance in diagnostics, as well as prognosis of disease progression, patient’s response to treatment options and the outcomes of the proposed therapy.